Literature DB >> 32358077

Recruiting TP53 to target chronic myeloid leukemia stem cells.

Steven Grant1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32358077      PMCID： PMC7193487          DOI： 10.3324/haematol.2019.246306

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   11.047


× No keyword cloud information.
  16 in total

1.  HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.

Authors:  L M S Lau; J K Nugent; X Zhao; M S Irwin
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

2.  CD34+ acute myeloid leukemia cells with low levels of reactive oxygen species show increased expression of stemness genes and can be targeted by the BCL2 inhibitor venetoclax.

Authors:  Katharina Mattes; Mylène Gerritsen; Hendrik Folkerts; Marjan Geugien; Fiona A van den Heuvel; Arthur Flohr Svendsen; Guoqiang Yi; Joost H A Martens; Edo Vellenga
Journal:  Haematologica       Date:  2019-11-14       Impact factor: 9.941

3.  p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells.

Authors:  L F Peterson; E Mitrikeska; D Giannola; Y Lui; H Sun; D Bixby; S N Malek; N J Donato; S Wang; M Talpaz
Journal:  Leukemia       Date:  2011-02-25       Impact factor: 11.528

4.  Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins.

Authors:  Simon N Willis; Lin Chen; Grant Dewson; Andrew Wei; Edwina Naik; Jamie I Fletcher; Jerry M Adams; David C S Huang
Journal:  Genes Dev       Date:  2005-05-18       Impact factor: 11.361

5.  Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.

Authors:  Bing Z Carter; Po Yee Mak; Hong Mu; Hongsheng Zhou; Duncan H Mak; Wendy Schober; Joel D Leverson; Bin Zhang; Ravi Bhatia; Xuelin Huang; Jorge Cortes; Hagop Kantarjian; Marina Konopleva; Michael Andreeff
Journal:  Sci Transl Med       Date:  2016-09-07       Impact factor: 17.956

Review 6.  Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate).

Authors:  L Novotny; N F Al-Tannak; L Hunakova
Journal:  Neoplasma       Date:  2016       Impact factor: 2.575

Review 7.  Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.

Authors:  Carolina Pavlovsky; Onyee Chan; Chetasi Talati; Javier Pinilla-Ibarz
Journal:  Future Oncol       Date:  2018-09-25       Impact factor: 3.404

8.  FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.

Authors:  Goichi Yoshimoto; Toshihiro Miyamoto; Siamak Jabbarzadeh-Tabrizi; Tadafumi Iino; Jennifer L Rocnik; Yoshikane Kikushige; Yasuo Mori; Takahiro Shima; Hiromi Iwasaki; Katsuto Takenaka; Koji Nagafuji; Shin-ichi Mizuno; Hiroaki Niiro; Gary D Gilliland; Koichi Akashi
Journal:  Blood       Date:  2009-10-06       Impact factor: 22.113

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  A-1210477, a selective MCL-1 inhibitor, overcomes ABT-737 resistance in AML.

Authors:  Qing Wang; Siguo Hao
Journal:  Oncol Lett       Date:  2019-09-19       Impact factor: 2.967
View more
  2 in total

Review 1.  Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

Authors:  Yammy Yung; Emily Lee; Hiu-Tung Chu; Pui-Kwan Yip; Harinder Gill
Journal:  Int J Mol Sci       Date:  2021-01-11       Impact factor: 5.923

Review 2.  Chronic myeloid leukemia stem cells: targeting therapeutic implications.

Authors:  Hanieh Mojtahedi; Niloufar Yazdanpanah; Nima Rezaei
Journal:  Stem Cell Res Ther       Date:  2021-12-18       Impact factor: 6.832
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.